<DOC>
	<DOCNO>NCT00472368</DOCNO>
	<brief_summary>This single center study help determine absorption , metabolism , excretion LBH589 ass safety efficacy LBH589 advance cancer patient standard therapy exists .</brief_summary>
	<brief_title>A Study Determine Absorption , Distribution , Metabolism , Excretion LBH589</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion Histologically cytologically confirm cancer patient include solid tumor , lymphoma , chronic hematological malignancy progression prior standard therapy . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 2 Normal renal hepatic function Exclusion criterion Patients central nervous system ( CNS ) involvement brain metastases Patients receive chemotherapy , investigational drug , undergone major surgery , receive wide field radiotherapy le 4 week ago Patients congenital long QT syndrome uncontrolled hypertension Patients myocardial infarction unstable angina within 6 month Congestive heart failure Impairment gastrointestinal ( GI ) function Use anticancer therapy Female patient pregnant breast feed Other protocol inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>lymphoma</keyword>
	<keyword>chronic hematological malignancy</keyword>
	<keyword>adult</keyword>
</DOC>